<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944123</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE-TAILOR</org_study_id>
    <nct_id>NCT02944123</nct_id>
  </id_info>
  <brief_title>Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)</brief_title>
  <official_title>An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      East Asian patients will be required optimal dose of newer P2Y12 inhibitors (prasugrel or
      ticagrelor) to determine the safer treatment and better outcome. Whether lower dose of these
      regimens are more adequate for clinical practice in Korea is unclear. Therefore, the
      investigators aim to evaluate efficacy and safety of half dose of new oral P2Y12 inhibitors
      in Korean patients with acute coronary syndrome (ACS) undergoing percutaneous coronary
      intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, newer oral P2Y12 receptor blockers (prasugrel or ticagrelor) have been
      strong recommendations for management of patients with ACS undergoing (PCI). These drugs
      provided more profound inhibitory effects than clopidogrel, which could lead to marked
      reduction in ischemic events, with relatively increase in bleeding complication, specific to
      low body weight, especially in women and East Asian patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Open-labeled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal platelet reactivity (OPR) rate</measure>
    <time_frame>At post-PCI 3 months.</time_frame>
    <description>OPR, indicate 85 to 208 for P2Y12 reaction units (PRU) or 16% to 50% for vasodilator-stimulated phosphoprotein (VASP)-platelet reactivity index (PRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>Post-PCI 6 months.</time_frame>
    <description>MACCE: composite of cardiac death, non-fatal myocardial infarction, repeat revascularization and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>Post-PCI 6 months.</time_frame>
    <description>BARC: Bleeding Academic Research Consortium (BARC ≥2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug side effects</measure>
    <time_frame>Post-PCI 6 months.</time_frame>
    <description>Dyspnea or ventricular pauses ≥3 sec</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 mg</intervention_name>
    <description>Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.</description>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <other_name>Plavix 75 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 5 mg</intervention_name>
    <description>Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.</description>
    <arm_group_label>Prasugrel 5 mg</arm_group_label>
    <other_name>Effient 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 45 mg</intervention_name>
    <description>Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.</description>
    <arm_group_label>Ticagrelor 45 mg</arm_group_label>
    <other_name>Brilinta 45 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients present with acute coronary syndrome undergoing primary PCI.

          -  Patients receive DAPT (conventional dose of P2Y12 inhibitors+aspirin) at least 1
             month.

          -  Patients provide written informed consent prior to enrollment.

        Exclusion Criteria:

          -  Low body weight (&lt;60kg).

          -  History of transient ischemic attack or stroke.

          -  History of upper gastrointestinal bleeding in recent 6 months.

          -  Renal dysfunction defined as serum creatinine &gt; 2.5 mg/dl

          -  Severe hepatic dysfunction defined as serum transaminase &gt; 3 times normal limit

          -  On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).

          -  Bleeding tendency.

          -  Thrombocytopenia defined by platelet &lt; 100,000/ml.

          -  Anemia defined by hemoglobin &lt; 10 g/dl.

          -  Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction
             with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin,
             nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and
             telithromycin.

          -  Known severe chronic obstructive pulmonary disease or bradycardia (sick sinus syndrome
             (SSS) or high degree AV block without pacemaker protection).

          -  Contraindication for study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moo Hyun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moo Hyun Kim, MD</last_name>
    <phone>+82-51-240-2976</phone>
    <email>kimmh@dau.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cai De Jin, MD</last_name>
    <phone>+82-10-9205-1188</phone>
    <email>jincaide1118@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moo Hyun Kim, MD</last_name>
      <phone>+82-51-240-2976</phone>
      <email>kimmh@dau.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circ J. 2015;79(11):2452-60. doi: 10.1253/circj.CJ-15-0112. Epub 2015 Sep 16.</citation>
    <PMID>26376600</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Moo Hyun Kim</investigator_full_name>
    <investigator_title>Professor, Dept. of Cardiology Dong-A University Hospital</investigator_title>
  </responsible_party>
  <keyword>Half dose</keyword>
  <keyword>Newer oral P2Y12 receptor inhibitors</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

